Human CD300F ELISA Kit

Name: Human CD300F ELISA Kit
SKU: DEIABL584
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

cell culture supernates, serum, heparin plasma, EDTA plasma

Species Reactivity

Human

Intended Use

Sandwich High Sensitivity ELISA kit for Quantitative Detection of human CD300F.

Storage

Store at 4°C for 6 months, at -20°C for 12 months. Avoid multiple freeze-thaw cycles(Shipped with wet ice.)

Detection Range

15.6pg/ml-1000pg/ml

Sensitivity

<10pg/ml

Citations

Have you cited DEIABL584 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Open Sesame: New Keys to Unlocking the Gate to Norovirus Infection

CELL HOST & MICROBE

Authors: Lingemann, Marit; Taube, Stefan

Abstract

Three recent papers highlight the impact of an entry receptor on murine norovirus pathogenesis. CD300lf was shown to be the first proteinaceous entry receptor for a norovirus, specialized intestinal epithelial cells constitute the reservoir for persistence, and a new link between the receptor and a lipid biosynthetic enzyme was revealed.

Prognostic Value ofCD200R1mRNA Expression in Head and Neck Squamous Cell Carcinoma

CANCERS

Authors: Chang, Hyun; Lee, Yun-Gyoo; Ko, Yoon Ho; Cho, Jang Ho; Choi, Jong-Kwon; Park, Keon Uk; Kang, Eun Joo; Lee, Keun-Wook; Lim, Sun Min; Kim, Jin-Soo; Lee, Hyun Woo; Kim, Min Kyoung; Hwang, In Gyu; Kim, Sangwoo; Nam, Byung-Ho; Kim, Hye Ryun

Abstract

Immune system dysfunction is associated with head and neck squamous cell carcinoma (HNSCC) development and progression and immune checkpoint inhibitors have demonstrated substantial survival benefits in platinum-refractory HNSCC; therefore, we examined the prognostic value of immune-related gene (IRG) expression in HNSCC. We analyzed the expression of 82 IRGs in 71 patients with HNSCC enrolled in a feasibility study for a prospective HNSCC biomarker-driven umbrella trial (Korean Cancer Study Group TRIUMPH study, NCT03292250).CD200R1was identified as an independent prognostic factor and validated in GEO and TCGA database.CD2000R1mRNA expression was found to be an independent favorable prognostic factor in patients with HNSCC. Moreover,CD200R1was found to affect genes and pathways associated with the immune response, while seven differentially expressed genes (CD8A, DOK2, CX3CR1, TYROBP, CXCL9, CD300LF, IFNG) were associated withCD200R1expression. Samples with higherCD200R1expression displayed higher tumor-infiltrating immune cell counts both in silico and in histological analysis. These findings will help in the development of more accurate prognostic tools and suggest CD200R1 modulation as a HNSCC immunotherapy.